# FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

> **NCT03283761** · PHASE2 · COMPLETED · sponsor: **Al B. Benson, III, MD** · enrollment: 39 (actual)

## Conditions studied

- Gastro-Esophageal Junction Adenocarcinoma
- Gastric Cancer

## Interventions

- **DRUG:** Nab-paclitaxel 150 mg/m^2
- **DRUG:** Oxaliplatin 85 mg/m^2
- **DRUG:** 5-FU 1200 mg/m^2 x 2 D
- **DRUG:** Leucovorin 400 mg/m^2

## Key facts

- **NCT ID:** NCT03283761
- **Lead sponsor:** Al B. Benson, III, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-21
- **Primary completion:** 2022-12-27
- **Final completion:** 2023-01-16
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2024-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283761, "FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03283761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*